Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type ...

A federal judicial panel on Monday ordered that a growing number of lawsuits accusing Novo Nordisk and Eli Lilly of causing ...

Claudia Oshry got real about her postpartum body. Oshry, 31, took to Instagram on Monday, December 15, to share that she’s ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

The health sector witnesses significant developments with Eli Lilly's promising weight-loss drug trials and a $40 million ...

Food-packed tables and endless spirits can present a special challenge for those taking GLP-1 medications like Wegovy, ...